Day: September 13, 2022

Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa® (octreotide). Mycapssa®The USPTO has issued to Amryt US Patent No. 11,400,159, with claims related to the Mycapssa® product. This patent will expire in September 2029. Amryt has nine Orange Book-listed patents for Mycapssa® with patent protection through December 2040.    Dr Joe Wiley, CEO of Amryt Pharma, commented: “We are always working to develop and extend our IP portfolio and today’s news further illustrates the robust IP protection enjoyed by Mycapssa®.” About Amryt Amryt is a global commercial-stage biopharmaceutical...

AskFrank integrates with any business’s chatbot, contact center, website or knowledge base using AI to provide answers simply and quickly to customers’ questions STOCKHOLM, Sweden — September 13th, 2022 — Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced it is launching AskFrank, its AI-enabled intelligent question-answering search engine. AskFrank integrates with a business’s existing customer engagement chatbots, contact center, website or knowledge base. Using AI to search content, it adds value to chatbots as an extension which provides answers to questions that are not available in a chatbot’s database by expanding its information access. Named AskFrank because the answers it gives are frank, direct and honest; it does not work with keywords like other search engines, but...

Suominen Corporation’s stock exchange release on September 13, 2022 at 1:00 p.m. EEST Suominen will publish its Financial Statements Release, Half Year Financial Report and two Interim Reports in 2023 as follows: February 3, 2023 – Financial Statements Release for 2022May 4, 2023 – Interim Report for January-March 2023August 9, 2023 – Half Year Financial Report for January-June 2023October 27, 2023 – Interim Report for January-September 2023 The Annual Report for 2022 will be published during the week starting on March 6, 2023 (week 10) at the latest. Suominen’s Annual General Meeting is planned to be held on Thursday, March 30, 2023. Suominen’s Board of Directors will summon the meeting at a later date. For more information: Emilia Peltola, VP, Communications and IR, tel. +358 10 214 3082 SUOMINEN...

TULIKIVI CORPORATION  MANAGERS’ TRANSACTIONS  13 SEPTEMBER AT 1:00 PM Tulikivi Corporation has received the following notification on 13 September 2022. Person subject to the notification requirement Name: Martti Purtola Position: Other senior manager Issuer: Tulikivi Oyj LEI: 743700GSL41H2DXZY963 Notification type: INITIAL NOTIFICATION Reference number: 18714/4/7 ____________________________________________ Transaction date: 2022-08-23 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009900583 Nature of the transaction: DISPOSAL Transaction details(1): Volume: 2406 Unit price: 0.73 EUR(2): Volume: 700 Unit price: 0.73 EUR(3): Volume: 1 Unit price: 0.73 EUR(4): Volume: 1 Unit price: 0.73 EUR(5): Volume: 300 Unit price: 0.73 EUR(6): Volume: 6592 Unit price: 0.73 EUR Aggregated transactions(6): Volume: 10000 Volume weighted...

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) 50mg (41%) and 28mg (29%) groups demonstrated fibrosis improvement AND resolution of NASH, six to eight times the placebo rate (5%) EFX-treated patients also experienced statistically significant improvements in liver fat, liver enzymes, noninvasive fibrosis markers, glycemic control, lipoproteins, and body weight Investor webcast at 8:00 am ET today to further discuss data SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...

HONOLULU, Sept. 13, 2022 (GLOBE NEWSWIRE) — Barnwell Industries, Inc. (NYSE American: BRN) today reported the sale of drilling rig by its wholly-owned Water Resources International, Inc. subsidiary for net consideration of approximately $550,000. Mr. Alexander C. Kinzler, Chief Executive Officer of Barnwell, commented, “We are pleased to report the sale of a drilling rig which will result in a gain to be recognized in our fiscal 4th quarter ending September 30, 2022. We previously sold another drilling rig in October 2021 for approximately $670,000 and the Company is taking these actions to reduce our contract drilling operating costs. We still own 5 rigs for drilling and pump installation. “In the North Twining Unit (“NTU”) in which Barnwell holds a 29% interest, there are now five horizontal wells on production with a sixth to...

FrontLobby and Equifax release findings that indicate Rent Reporting may benefit millions of Canadians over time TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) — FrontLobby and Equifax® Canada joined forces in 2018 to start a rent reporting program. Today, the two organizations are releasing multi-year findings that indicate rent reporting through FrontLobby can substantially benefit the financial well-being of Canada’s 5+ million renting households. According to Equifax, in Canada it is estimated that more than 3 million people aged 18+ are “credit invisible” meaning these individuals either do not have a credit file or the credit information on file is insufficient to generate credit scores. An additional 7 million may have 2 or less credit accounts on their credit file, meaning they are considered to have limited credit history or...

Company Announcement No. 981 On 26 July 2022, we initiated a share buyback programme, as described in Company Announcement No. 973. According to the programme, the company will in the period from 26 July 2022 until 24 October 2022 purchase own shares up to a maximum value of DKK 7,000 million, and no more than 14,000,000 shares, corresponding to 5.98% of the current share capital of DSV A/S. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day   Number of shares bought back   Average transaction price   Amount DKK               Accumulated trading for days 1-29 2,046,169   1,178.92   2,412,261,23130: 5 September 2022 68,000   1,049.13   71,340,84031: 6...